Amarna Therapeutics
Leiden
About Amarna Therapeutics
Based on its unique properties SVac is ideally suited for developing next generation effective gene and immune-therapies. In order to realize our ambition to become the leading global gene therapy company they formed a worldwide consortium of key players in the virology, vector production, immunology, ophthalmology, oncology, neurology and gene therapy fields of research. With major regulatory, legal and intellectual property firms, they are developing a range of innovative and effective interventions for genetic disorders, degenerative diseases, allergies and cancer. Interventions that will dramatically improve patients’ life expectancy and quality and moreover will significantly reduce the health care costs of the society in general.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $16.7M
- Last round: Grant (Jan 2022)
- Website: amarnatherapeutics.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/amarna-therapeutics-70994 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.